StreetAlpha.app
Home › Stocks › BLTE

Belite Bio, Inc (BLTE)

Healthcare
$157.72
▼ −2.98%
LAST CLOSE · NOV 17

Belite Bio is a San Diego drug developer working on oral treatments for degenerative retinal diseases that cause vision loss. It last closed at $157.72 on Nov 17, down 2.98% on the day. BLTE last reported earnings on Thu, Nov 12, 2026. The average 12-month price target from 4 analysts is $251.00 (+59.1% from the last close), with a high of $314.00 and a low of $215.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $1.2M.

AI Auto Pilots
Is BLTE in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Net income
−$77.6M
Free cash flow
−$37.1M
Balance sheet
Cash & equivalents
$352.9M
At Dec 31
Shareholder equity
$770.5M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$9.7M−$9.7MFY2021FY2022: −$12.6M−$12.6MFY2022FY2023: −$31.6M−$31.6MFY2023FY2024: −$36.1M−$36.1MFY2024FY2025: −$77.6M−$77.6MFY2025

From BLTE's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Per share figures are left out because the US listing can represent a different number of shares.

Last report
Nov 12
2026 · Before the open (BMO)
Reported EPS
-$0.65
vs -$0.73 est. · beat
Year-ago EPS
-$0.65
Same quarter last year
Options-implied move
±7.9%
Priced in before that report
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on BLTE in the past 90 days
Average 12-month target
$251.00
▲ 59.1% upside

Based on 4 analysts who set a price target on BLTE in the past 90 days. The average target is $251.00, with a high of $314.00 and a low of $215.00, compared with the last close of $157.72.

Low $215.00Avg $251.00High $314.00
Blue marker: last close $157.72
Highest target$314.00
Average target$251.00
Lowest target$215.00
Latest rating changes
Canaccord GenuityTarget raised
Nov 16Buy$303 → $314
MizuhoTarget lowered
Nov 16Buy$234 → $230
Leerink PartnersMaintained
Nov 13Buy$215
MizuhoTarget raised
Sep 9Buy$215 → $234
HC Wainwright & Co.Target raised
Sep 8Buy$214 → $245
DateFirmActionRatingPrice target
Nov 16Canaccord GenuityTarget raisedBuy$303 → $314
Nov 16MizuhoTarget loweredBuy$234 → $230
Nov 13Leerink PartnersMaintainedBuy$215
Sep 9MizuhoTarget raisedBuy$215 → $234
Sep 8HC Wainwright & Co.Target raisedBuy$214 → $245
Loading…

Technical Analysis

BLTE · as of the Nov 17 close · updated after every close
Turning up

The stock sits between its 20 and 50 day averages. It is 1% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the Pivot S1 at $155.42, and the nearest resistance the Pivot at $158.81.

Short trendBullish
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityNormal, 5.0%/day
Key levels
$200.0052 week high+26.8%
$161.12Pivot R1+2.2%
$160.00200 day average+1.4%
$159.5650 day average+1.2%
$159.33100 day average+1.0%
$158.90Swing high (Jul 7)+0.7%
$158.81Pivot+0.7%
$157.72Last close
$155.42Pivot S1−1.5%
$153.7820 day average−2.5%
$151.50Swing low (Jul 29)−3.9%
$105.8852 week low−32.9%
Indicators
RSI (14)51.09Middle of its rangeNeutral
MACD1.43Above its signal lineBullish
Stochastic68.7Middle of its rangeNeutral
ADX (14)18.6No clear trend
Williams %R-44.1Oversold below −80, overbought above −20Neutral
CCI (20)75.6Oversold below −100, overbought above 100Neutral
Rate of change+3.6%Change over 10 sessionsBullish
ATR (14)$7.84Typical daily range, 5.0% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for BLTE

What happened before

See how BLTE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BLTE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BLTE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in BLTE in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.8M
Largest print
$1.2M
Loading…

BLTE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 42 selling
  • ●Shares held by funds -0.6%
  • ▲Funds holding +15
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9681+18.5%
In funds' top 10550.0%
Held by funds–––
New / increased28 / 2922 / 28+14.0%
Reduced / sold out30 / 1222 / 17+7.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BLTE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BLTE is in one of them and how their past BLTE trades turned out.

BLTE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BLTE in an article yet. Here's the latest on the wider market.

About Belite Bio

Belite Bio is a drug development company based in San Diego, California. It is developing tinlarebant, a tablet taken once a day, for people with degenerative retinal diseases that cause progressive vision loss, including geographic atrophy and Stargardt disease type 1. The company also has an earlier stage oral compound aimed at metabolic conditions such as fatty liver disease and type 2 diabetes. Its intended users are patients with these eye conditions and the doctors who would treat them if a product is approved.

Headquarters
San Diego, CA